1. Barnhart, K. T., Pretorius, E. S., Timbers, K., Shera, D., Shabbout, M., & Malamud, D. (2004). In vivo distribution of a vaginal gel: MRI evaluation of the effects of gel volume, time and simulated intercourse. Contraception, 70(6), 498–505.
2. Bax, R., Douville, K., McCormick, D., Rosenberg, M., Higgins, J., & Bowden, M. (2002). Microbicides—evaluating multiple formulations of C31G. Contraception, 66(5), 365–368.
3. Bentley, M. E., Morrow, K., Fullem, A., Chesney, M. A., Horton, S. D., Rosenberg, Z., et al. (2000). Acceptability of a novel vaginal microbicide during a safety trial among low-risk women. Family Planning Perspectives, 32(4), 184–188.
4. Boonstra, H. (2000). Campaign to accelerate microbicide development for STD prevention gets under way. The Guttmacher Report on Public Policy, 3, 3–4.
5. Coggins, C., Blanchard, K., Alvarez, F., Brache, V., Weisberg, E., Kilmarx, P., et al. (2000). Safety and acceptability of lambda-carageenan-containing vaginal microbicide gel PC-503. Paper presented at the Microbicide 2000, Washington, DC.